Note 4.

Stock-Based Compensation

Stock-based compensation is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense over the requisite service period (generally the vesting period of the grant). The company recognizes the impact of forfeitures as forfeitures occur.

Our net loss for the quarters ended December 26, 2017 and December 27, 2016 includes $118,000 and $199,000, respectively, of compensation costs related to our stock-based compensation arrangements.

Stock Option awards

The Company measures the compensation cost associated with stock option awards by estimating the fair value of the award as of the grant date using the Black-Scholes pricing model. The Company believes that the valuation technique and the approach utilized to develop the underlying assumptions are appropriate in calculating the fair values of the Company’s stock options and stock awards granted during the first fiscal quarter ended December 26, 2017. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by the employees who receive equity awards.

During the quarter ended December 26, 2017, the Company granted a total of 12,963 incentive stock options, from available shares under its 2008 Plan, as amended, with an exercise price of $2.70 and a per-share weighted average fair value of $1.95.

During the quarter ended December 27, 2016, the Company granted a total of 149,899 incentive stock options, from available shares under its 2008 Plan, as amended, with exercise prices between of $3.05 and $3.15 and per-share weighted average fair values between $2.17 and $2.30.

In addition to the exercise and grant date prices of the stock option awards, certain weighted average assumptions that were used to estimate the fair value of stock option grants are listed in the following table:

	Quarter Ended 12/26/17 Incentive and Non-Statutory Stock Options	Quarter Ended 12/27/16 Incentive and Non-Statutory Stock Options
Expected term (years)	7.5	6.5 to 7.5
Expected volatility	75.67%	75.66% to 80.70%
Risk-free interest rate	2.17%	1.49% to 2.40%
Expected dividends	0	0

We estimate expected volatility based on historical weekly price changes of our common stock for a period equal to the current expected term of the options. The risk-free interest rate is based on the United States treasury yields in effect at the time of grant corresponding with the expected term of the options. The expected option term is the number of years we estimate that options will be outstanding prior to exercise considering vesting schedules and our historical exercise patterns.

The following table summarizes stock option activity for the quarter ended December 26, 2017 under all plans:

	Shares			Weighted Average Exercise Price		Weighted Avg. Remaining Contractual Life (Yrs.)
Outstanding-at beginning of year		681,922		$	4.25
Options granted		12,963		$	2.70
Options exercised		0
Forfeited		(2,970	)	$	4.04
Expired		(2,933	)	$	17.25
Outstanding December 26, 2017		688,982		$	4.17	6.5
Exercisable December 26, 2017		467,207		$	3.94	5.7

As of December 26, 2017, the aggregate intrinsic value of the outstanding and exercisable options was $58,000 and $58,000, respectively. Only options whose exercise price is below the current market price of the underlying stock are included in the intrinsic value calculation.

As of December 26, 2017, the total remaining unrecognized compensation cost related to non-vested stock options was $485,000 and is expected to be recognized over a weighted average period of approximately 1.8 years.

There were no stock options exercised during the quarters ended December 26, 2017 and December 27, 2016.

Restricted Stock Grants

During the quarter ended December 26, 2017, the Company granted a total of 37,037 shares of restricted stock from available shares under its 2008 Plan, as amended. The shares were issued with a grant date fair market value of $2.70 which is equal to the closing price of the stock on the date of the grant. The restricted stock grant vests over three years following the grant date.

During the quarter ended December 27, 2016, the Company granted a total of 101,094 shares of restricted stock from available shares under its 2008 Plan, as amended. The shares were issued with a grant date fair market value of $3.15 which is equal to the closing price of the stock on the date of the grant. The restricted stock grant vests over three years following the grant date.

A summary of the status of non-vested restricted stock as of December 26, 2017 is presented below.

	Shares			Grant Date Fair Value Per Share
Non-vested shares at beg of year		115,039		$	3.15 to $8.60
Granted		37,037		$	2.70
Vested		(41,038	)	$	3.15 to $4.18
Non-vested shares at December 26, 2017		111,038		$	2.70 to $8.60

As of December 26, 2017, there was $314,000 of total unrecognized compensation cost related to non-vested restricted stock. This cost is expected to be recognized over a weighted average period of approximately 1.4 years.